96 related articles for article (PubMed ID: 14606374)
41. [Prognostic factors in neuroblastoma in children].
Blinov VM; Bukhny AF; Izrail'skaia MA; Dzhalalov KD
Vopr Onkol; 1984; 30(5):21-31. PubMed ID: 6730411
[TBL] [Abstract][Full Text] [Related]
42. Minimal residual disease is a prognostic marker for neuroblastoma with bone marrow infiltration.
Cai JY; Pan C; Tang YJ; Chen J; Ye QD; Zhou M; Xue H; Tang JY
Am J Clin Oncol; 2012 Jun; 35(3):275-8. PubMed ID: 21537148
[TBL] [Abstract][Full Text] [Related]
43. [Impact of complete resection on survival of patients with large neuroblastoma].
Lobato R; Queizán A; Martínez L; Díaz M; Gámez M; Tovar JA
Cir Pediatr; 2000 Jan; 13(1):14-5. PubMed ID: 12602016
[TBL] [Abstract][Full Text] [Related]
44. [Present status of neuroblastoma mass screening in Japan. Neuroblastoma-Committee of the Japanese Childhood Cancer Society].
Sawada T; Nagahara N; Ohi R; Yamamoto K; Okabe I; Hanawa Y; Hashizume K; Matsui I; Ohkawa H; Tunoda A
Gan To Kagaku Ryoho; 1990 Dec; 17(12):2319-26. PubMed ID: 2260868
[TBL] [Abstract][Full Text] [Related]
45. The efficacy of delayed surgery in children with high-risk neuroblastoma.
Varan A; Kesik V; Şenocak ME; Kale G; Akyüz C; Büyükpamukçu M
J Cancer Res Ther; 2015; 11(2):268-71. PubMed ID: 26148582
[TBL] [Abstract][Full Text] [Related]
46. [Better survival in neuroblastoma?].
Monclair T; Storm-Mathisen I
Tidsskr Nor Laegeforen; 1997 Apr; 117(10):1466-8. PubMed ID: 9198924
[TBL] [Abstract][Full Text] [Related]
47. Additional Therapies to Improve Metastatic Response to Induction Therapy in Children With High-risk Neuroblastoma.
Schrey D; Vaidya SJ; Levine D; Pearson AD; Moreno L
J Pediatr Hematol Oncol; 2015 Apr; 37(3):e150-3. PubMed ID: 26201036
[TBL] [Abstract][Full Text] [Related]
48. [Therapy of abdominal neuroblastoma in Essen].
Lange R; Kremens B; Grigoleit U; Erhard J
Langenbecks Arch Chir Suppl Kongressbd; 1996; 113():1073-7. PubMed ID: 9101784
[TBL] [Abstract][Full Text] [Related]
49. The degree of tumor volume reduction during the early phase of induction chemotherapy is an independent prognostic factor in patients with high-risk neuroblastoma.
Yoo SY; Kim JS; Sung KW; Jeon TY; Choi JY; Moon SH; Son MH; Lee SH; Yoo KH; Koo HH
Cancer; 2013 Feb; 119(3):656-64. PubMed ID: 22952047
[TBL] [Abstract][Full Text] [Related]
50. Biological analysis of neuroblastoma in mass screened negative cases.
Ishimoto K; Kiyokawa N; Fujita H; Yabuta K; Ohya T; Miyano T; Shinohara T; Sera Y
Prog Clin Biol Res; 1991; 366():603-8. PubMed ID: 2068179
[No Abstract] [Full Text] [Related]
51. [Value of prognostic factors in the Austrian A-NB87 Neuroblastoma Study].
Ladenstein R; Ambros PF; Urban C; Ambros IM; Fink FM; Zoubek A; Grienberger H; Schmitt K; Kerbl R; Horcher E; Amann G; Höfler G; Heinzl H; Gadner H; Mutz I
Klin Padiatr; 1996; 208(4):210-20. PubMed ID: 8926686
[TBL] [Abstract][Full Text] [Related]
52. Molecular biology and genetics of neuroblastoma.
Tay JS
J Singapore Paediatr Soc; 1991; 33(3-4):80-7. PubMed ID: 1812339
[No Abstract] [Full Text] [Related]
53. Neuroblastoma in adults: Incidence and survival analysis based on SEER data.
Esiashvili N; Goodman M; Ward K; Marcus RB; Johnstone PA
Pediatr Blood Cancer; 2007 Jul; 49(1):41-6. PubMed ID: 16628557
[TBL] [Abstract][Full Text] [Related]
54. Is the mass screening for neuroblastoma ineffective?
Nishi M; Hanai J; Fujita K; Ichimiya H; Tanaka T; Hatae Y; Takeda T
J Exp Clin Cancer Res; 2003 Dec; 22(4):673-6. PubMed ID: 15053313
[TBL] [Abstract][Full Text] [Related]
55. The characteristics of mediastinal neuroblastoma.
Suita S; Tajiri T; Sera Y; Takamatsu H; Mizote H; Ohgami H; Kurosaki N; Hara T; Okamura J; Miyazaki S; Sugimoto T; Kawakami K; Tsuneyoshi M; Tasaka H; Yano H; Akiyama H; Ikeda K
Eur J Pediatr Surg; 2000 Dec; 10(6):353-9. PubMed ID: 11215774
[TBL] [Abstract][Full Text] [Related]
56. Mass screening for neuroblastoma at 6 months of age.
Miura Y; Kami M; Tsubokura M; Takei N; Komatsu T
Lancet; 2008 Aug; 372(9636):372-3; author reply 373. PubMed ID: 18675685
[No Abstract] [Full Text] [Related]
57. Improved survival of children with neuroblastoma between 1979 and 2005: a report of the Italian Neuroblastoma Registry.
Haupt R; Garaventa A; Gambini C; Parodi S; Cangemi G; Casale F; Viscardi E; Bianchi M; Prete A; Jenkner A; Luksch R; Di Cataldo A; Favre C; D'Angelo P; Zanazzo GA; Arcamone G; Izzi GC; Gigliotti AR; Pastore G; De Bernardi B
J Clin Oncol; 2010 May; 28(14):2331-8. PubMed ID: 20351331
[TBL] [Abstract][Full Text] [Related]
58. [Report on long-term follow-up of stage IV neuroblastoma].
Tang JY; Pan C; Liu Y
Zhonghua Er Ke Za Zhi; 2009 Mar; 47(3):225-7. PubMed ID: 19573442
[No Abstract] [Full Text] [Related]
59. [Central nervous system involvement at diagnosis and at relapse in children with neuroblastoma].
Wieczorek A; Balwierz W; Wyrobek Ł; Garus K; Kwiatkowski S; Kwiecińska K; Walicka-Soja K
Przegl Lek; 2010; 67(6):399-403. PubMed ID: 21344769
[TBL] [Abstract][Full Text] [Related]
60. The objective of cancer screening is to reduce disease-specific mortality, including screening for neuroblastoma.
Parker L
Med Pediatr Oncol; 2000 Jan; 34(1):82-3. PubMed ID: 10611600
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
